1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?

  • August 2013
  • Firstword Pharma
Report ID: 2011382

Summary

Table of Contents

Scope

This year looks set to be one of notable evolution for the US chronic obstructive pulmonary disease (COPD) market and GlaxoSmithKline's respiratory franchise in particular.
The company secured FDA approval for its once-daily LABA/ICS therapy Breo Ellipta in May and its proposed once-daily LAMA/LABA combination Anoro Ellipta has been set a PDUFA date of December 18. Before securing an early Christmas present, however, GlaxoSmithKline will have to negotiate an advisory committee meeting next month (September 10).
With progression of Novartis' QVA149 delayed in the US, Anoro is poised to be the first LAMA/LABA combination to reach the market in the country, although a number of key questions await GlaxoSmithKline at September's AdCom.
Most pertinently, suggested analysts at JP Morgan last week, could be the AdCom's view towards the dosing profile of Anoro. JP Morgan analyst James Gordon postulates that based on "noisy dose response data," the panel could question whether the optimal dose and dosing frequency for the umeclidinium LABA component has been identified. Furthermore, could the panel recommend that twice-daily dosing may be better?
Such an outcome would seemingly have significant commercial implications, given that the race to bring LABA/LAMA combinations to market is notably focused on once-daily products. Not so, argues Pearl Therapeutics CEO Charles Bramlage, who recently told FirstWord that he believes significant commercial opportunity exists for a twice-daily LAMA/LABA combination, given the risk that the efficacy of a once-daily product will wane over a 24-hour period (see In Focus: Can Pearl Therapeutics support AstraZeneca's late dash in the respiratory market? - FirstWord speaks to CEO Charles Bramlage).
AstraZeneca is banking on Bramlage being right. The UK drugmaker recently acquired Pearl for a potential cost of up to $1 billion; a move that is designed to accelerate its own efforts to expand its respiratory portfolio. AstraZeneca and Pearl's PT003 is expected to reach the market by around 2016, potentially some time behind competing LAMA/LABA combinations.
A key differentiator for PT003 – despite its later market entry and confirmed twice-daily dosing – will be the inhaler device, noted AstraZeneca CEO Pascal Soriot at the beginning of the month when the company announced its Q2 results. PT003 will be delivered in a pressured metered dose inhaler (pMDI) instead of a dry powder inhaler (DPI), the type of device being used by other LAMA/LABA developers. A pMDI inhaler could offer an ease-of-use/convenience advantage, particularly in older or frail COPD patients, note analysts at JP Morgan.
Combined with a porous particle formulation technology, Pearl is confident that PT003 will deliver the necessary efficacy at lower doses, a potential advantage suited to the pMDI approach (management has previously suggested the challenge in delivering a small dose via a DPI as the drug is not always uniformly dispersed).


Reasons to Buy This Report

This week's FirstWord Physician Views poll will ask:

• To what percentage of COPD patients they currently prescribe both a LABA monotherapy and a LAMA monotherapy?
• What percentage of patients currently receiving a LABA therapy would they expect to switch to a combination LABA/LAMA product two years after the first product of this type gains approval?
• What percentage of patients currently receiving a LABA/ICS therapy they would anticipate switching to a combination LABA/LAMA product?
• To what percentage of COPD patients they would favour prescribing a twice-daily therapy for fear that a once-daily treatment would have a diminished effect later in the day?
• In what percentage of patients being prescribed a LABA/LAMA combination therapy they would prefer to prescribe a pMDI instead of a DPI?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • May 2017
    2 pages
  • Therapy  

  • United States  

View report >

Therapy Market in the US

  • May 2017
    3 pages
  • Therapy  

    Arthritis  

  • United States  

View report >

Hormone and Therapy Market in Pakistan and the US

  • May 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Related Market Segments :

Therapy
Pulmonary Delivery

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.